A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

NCT07064759 ·Status: RECRUITING ·Phase: PHASE3

Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.

NCT03714308 ·Status: COMPLETED

Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye

NCT02581891 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)

NCT02818998 ·Status: COMPLETED ·Phase: PHASE3

A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

NCT06491914 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

NCT06864988 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)

NCT01722045 ·Status: COMPLETED ·Phase: PHASE4

A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT07215234 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration

NCT04126317 ·Status: COMPLETED ·Phase: PHASE2

Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept

NCT02125864 ·Status: COMPLETED ·Phase: PHASE4

Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)

NCT05275205 ·Status: COMPLETED ·Phase: PHASE2

A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration

NCT04200248 ·Status: COMPLETED ·Phase: PHASE2

Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects

NCT03211234 ·Status: COMPLETED ·Phase: PHASE2

Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept

NCT03468296 ·Status: UNKNOWN ·Phase: PHASE4

Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START

NCT02246829 ·Status: COMPLETED ·Phase: PHASE4

A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment

NCT05473715 ·Status: TERMINATED ·Phase: PHASE4

A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

NCT06591598 ·Status: COMPLETED ·Phase: PHASE4

Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)

NCT03411941 ·Status: COMPLETED

A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD).

NCT04641234 ·Status: COMPLETED

Analysis of naïve Patients With Age-related Macular Degeneration of the Neovascular Type and Treated With Aflibercept (Eylea®) in "Treat-and-extend" at CHU Brugmann

NCT04891835 ·Status: COMPLETED

Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD

NCT01414153 ·Status: COMPLETED ·Phase: PHASE2

Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients

NCT03382587 ·Status: COMPLETED

Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration

NCT02157077 ·Status: COMPLETED ·Phase: PHASE3

Intravitreal Aflibercept for Submacular Hemorrhage

NCT03169660 ·Status: COMPLETED ·Phase: PHASE4

ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration

NCT04744662 ·Status: COMPLETED ·Phase: PHASE1